How antidepressants help depression: Mechanisms of action and clinical response

Journal of Clinical Psychiatry

Volumn 65, Issue SUPPL. 4, 2004, Pages 25-30

  Delgado, Pedro L ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BIOGENIC AMINE;

DEPRESSION; HUMAN; PSYCHOLOGICAL ASPECT; REVIEW; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; BIOGENIC MONOAMINES; DEPRESSIVE DISORDER; HUMANS; TREATMENT OUTCOME;

EID: 2142715377     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Bolden-Watson C, Richelson E. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 1993;52:1023-1029
2. Owens MJ. Selectivity of antidepressants: from the monoamine hypothesis of depression to the SSRI revolution and beyond. J Clin Psychiatry 2004;65(suppl 4):5-10
3. Lucki I, O'Leary OF. Distinguishing roles for norepinephrine and serotonin in the behavioral effects of antidepressant drugs. J Clin Psychiatry 2004;65(suppl 4):11-24
4. Gorman JM, Korotzer A, Su G. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectr 2002;7[4 suppl 1]:40-44
5. Nelson JC. A review of the efficacy of serotonergic and noradrenergic reuptake inhibitors for treatment of major depression. Biol Psychiatry 1999;46:1301-1308
6. Tyrer PJ, Lee I, Edwards JG, et al. Prognostic factors determining response to antidepressant drugs in psychiatric out-patients and general practice. J Affect Disord 1980;2:149-156
7. Aberg-Wistedt A. A double-blind study of zimelidine, a serotonin uptake inhibitor, and desipramine, a noradrenaline uptake inhibitor, in endogenous depression, 1: clinical findings. Acta Psychiatr Scand 1982;66: 50-65
8. Goodman WK, Price LH, Delgado PL, et al. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: comparison of fluvoxamine and desipramine. Arch Gen Psychiatry 1990;47:577-585
9. Leonard BE. The comparative pharmacology of new antidepressants. J Clin Psychiatry 1993;54(suppl 8):3-15
10. Lelliott PT, Monteiro WO. Drug treatment of obsessive-compulsive disorder. Drugs 1986;31:75-80
11. Reist C, Kauffmann CD, Haier RJ, et al. A controlled trial of desipramine in 18 men with posttraumatic stress disorder. Am J Psychiatry 1989;146: 513-516
12. Dow B, Kline N. Antidepressant treatment of posttraumatic stress disorder and major depression in veterans. Ann Clin Psychiatry 1997;9:1-5
13. Canive JM, Clark RD, Calais LA, et al. Bupropion treatment in veterans with posttraumatic stress disorder: an open study. J Clin Psychopharmacol 1998;18:379-383
14. Blackwell B. Side effects of antidepressant drugs. In: Hales RE, Frances AJ, eds. The American Psychiatric Association Annual Review. Arlington, Va: American Psychiatric Press; 1987:724-725
15. Kalus O, Asnis GM, Rubinson E, et al. Desipramine treatment in panic disorder. J Affect Disord 1991;21:239-244
16. Lydiard RB, Morton WA, Emmanuel NP, et al. Preliminary report: placebo-controlled, double-blind study of the clinical and metabolic effects of desipramine in panic disorder. Psychopharmacol Bull 1993;29:183-188
17. Villarreal G. Desipramine plasma levels and treatment response in panic disorder [letter]. Can J Psychiatry 1995;40:110-111
18. Versiani M, Cassano G, Perugi G, et al. Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder. J Clin Psychiatry 2002;63:31-37
19. Sasson Y, Iancu I, Fux M, et al. A double-blind crossover comparison of clomipramine and desipramine in the treatment of panic disorder. Eur Neuropsychopharmacol 1999;9:191-196
20. Rush AJ, Batey SR, Donahue RM, et al. Does pretreatment anxiety predict response to either bupropion SR or sertraline? J Affect Disord 2001;64:81-87
21. Delgado PL, Charney DS, Price LH, et al. Serotonin function and the mechanism of antidepressant action: reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 1990;47:411-418
22. Delgado PL, Miller HL, Salomon RM, et al. Monoamines and the mechanism of antidepressant action: effects of catecholamine depletion on mood of patients treated with antidepressants. Psychopharmacol Bull 1993;29:389-396
23. Delgado PL, Miller HL, Salomon RM. Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. Biol Psychiatry 1999;46:212-220
24. Engelman K, Horwitz D, Jequier E, et al. Biochemical and pharmacologic effects of alpha-methyltyrosine in man. J Clin Invest 1968;47: 577-594
25. Bunney WE, Brodie HK, Murphy DL, et al. Studies of alpha-methyl-para- tyrosine, L-dopa, and L-tryptophan in depression and mania. Am J Psychiatry 1971;127:872-881
26. Bunney WE, Davis JM. Norepinephrine in depressive reactions: a review. Arch Gen Psychiatry 1965;13:483-494
27. Miller HL, Delgado PL, Salomon RM, et al. Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression. Arch Gen Psychiatry 1996;53:117-128
28. Harper AE, Benevenga NJ, Wohlhueter RM. Effects of ingestion of disproportionate amounts of amino acids. Physiol Rev 1970;50:428-558
29. Serotonin now: clinical implications of inhibiting its synthesis with para-chlorophenylalanine. Ann Intern Med 1970;73:607-630
30. Shopsin B, Gershon S, Goldstein M, et al. Use of synthesis inhibitors in defining a role for biogenic amines during imipramine treatment in depressed patients. Psychopharmacol Commun 1975;1:239-249
31. Shopsin B, Friedman E, Gershon S. Parachlorophenylalanine reversal of tranylcypromine effects in depressed patients. Arch Gen Psychiatry 1976;33:811-819
32. Curzon G. Relationships between plasma, CSF and brain tryptophan. J Neural Transm Suppl 1979;15:81-92
33. Rose WC, Haines WJ, Warner DT. The amino acid requirements of man. J Biol Chem 1954;206:421-430
34. Young SN, Ervin FR, Pihl RO, et al. Biochemical aspects of tryptophan depletion in primates. Psychopharmacology (Berl) 1989;98:508-511
35. Young SN, Smith SE, Pihl RO, et al. Tryptophan depletion causes a rapid lowering of mood in normal males. Psychopharmacology (Berl) 1985;87: 173-177
36. Young VR, Hussein MA, Murray E. Tryptophan intake, spacing of meals, and diurnal fluctuations of plasma tryptophan in men. Am J Clin Nutr 1969;22:1563-1567
37. Young VR, Hussein MA, Murray E. Plasma tryptophan response curve and its relation to tryptophan requirements in young adult men. J Nutr 1971;101:45-59
38. Delgado PL, Charney DS, Price LH, et al. Neuroendocrine and behavioral effects of dietary tryptophan restriction in healthy subjects. Life Sci 1989;45:2323-2332
39. Moja EA, Cipolla P, Castoldi D, et al. Dose-response decrease in plasma tryptophan and in brain tryptophan and serotonin after tryptophan-free amino acid mixtures in rats. Life Sci 1989;44:971-976
40. Perez-Cruet J, Chase TN, Murphy DL. Dietary regulation of brain tryptophan metabolism by plasma ratio of free tryptophan and neutral amino acids in humans. Nature 1974;248:693-695
41. Delgado PL, Price LH, Miller HL, et al. Serotonin and the neurobiology of depression: effects of tryptophan depletion in drug-free depressed patients. Arch Gen Psychiatry 1994;51:865-874
42. Delgado PL, Price LH, Miller HL, et al. Rapid serotonin depletion as a provocative challenge test for patients with major depression: relevance to antidepressant action and the neurobiology of depression. Psychopharmacol Bull 1991;27:321-330
43. Moreno FA, Gelenberg AJ, Heninger GR. Tryptophan depletion and depressive vulnerability. Biol Psychiatry 1999;46:498-505
44. Carpenter LL, Anderson GM, Pelton GH. Tryptophan depletion during continuous CSF sampling in healthy human subjects. Neuropsychopharmacology 1998;19:26-35
45. Moreno FA, McGavin C, Malon TP. Tryptophan depletion selectively reduces CSF 5-HT metabolites in healthy young men: results from single lumbar puncture sampling technique. Int J Neuropsychopharmacol 2000;3:277-283
46. Nishizawa S, Benkelfat C, Young SN, et al. Differences between males and females in rates of serotonin synthesis in human brain. Proc Natl Acad Sci U S A 1997;94:5308-5313
47. Benkelfat C, Ellenbogen MA, Dean P. Mood-lowering effect of tryptophan depletion: enhanced susceptibility in young men at genetic risk for major affective disorders. Arch Gen Psychiatry 1994;51:687-697
48. Smith KA, Fairburn CG, Cowen PG. Relapse of depression after rapid depletion of tryptophan. Lancet 1997;349:915-919
49. Leyton M, Young SN, Blier P. The effect of tryptophan depletion on mood in medication-free, former patients with major affective disorder. Neuropsychopharmacology 1997;16:294-297
50. Moreno FA, Heninger GR, McGahuey CA. Tryptophan depletion and risk of depression relapse: a prospective study of tryptophan depletion as potential predictor of depressive episodes. Biol Psychiatry 2000;48:327-329
51. Miller HL, Delgado PL, Salomon RM, et al. Effects of (alpha)-methyl-para- tyrosine (AMPT) in drug-free depressed patients. Neuropsychopharmacology 1996;14:151-157
52. Sulser F, Sanders-Bush E. The serotonin-norephinephrine link hypothesis of affective disorders: receptor-receptor interactions in the brain. In: Ehrlich YH, ed. Molecular Basics of Neuronal Responsiveness. New York, NY: Plenum Press; 1997:439-502
53. Bymaster FP, Zhang W, Carter PA, et al. Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology (Berl) 2002;160:353-361
54. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997;54:597-606
55. Duman RS, Malberg J, Thome J. Neural plasticity to stress and antidepressant treatment. Biol Psychiatry 1999;46:1181-1191
56. Hyman SE, Nestler EJ. Initiation and adaptation: a paradigm for understanding psychotropic drug action. Am J Psychiatry 1996;153: 151-162
57. Rajkowska G. Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biol Psychiatry 2000;48: 766-777